Year Founded
2009
Ownership
Public
Employees
~500
Therapeutic Areas
OphthalmologyImmunologyRare DiseasesNeurology
Stage
Phase 3
Modalities
Gene therapyAdeno-associated virus (AAV)

REGENXBIO General Information

Clinical-stage biotechnology company developing gene therapy treatments using proprietary NAV Technology Platform. Lead programs include ABBV-RGX-314 for retinal diseases, RGX-202 for Duchenne, and RGX-121 for MPS II.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office

Drug Pipeline

ABBV-RGX-314
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to REGENXBIO's pipeline data

Book a demo

Key Partnerships

AbbVie, Nippon Shinyaku

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

REGENXBIO Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view REGENXBIO's complete valuation and funding history, request access »

REGENXBIO Licensing Deals

AssetLicenseeDateTherapeutic Area
clemidsogene lanparvovecNippon ShinyakuMar 1, 2025Neurodegenerative
surabgene lomparvovecAbbVieN/AOphthalmology
AMT-260uniQureJun 1, 2020Neurology
RP-A501Rocket PharmaceuticalsNov 19, 2018Rare genetic
RGX-121Nippon ShinyakuJan 14, 2025Rare genetic
RGX-111Nippon ShinyakuJan 14, 2025Rare genetic
zolgensmaNovartis Gene TherapiesMar 1, 2014Rare genetic
zolgensmaHealthcare Royalty ManagementDec 1, 2020Rare genetic
abbv-rgx-314AbbVieSep 1, 2021Ophthalmology
ABBV-RGX-314AbbVieN/AOphthalmology
zolgensmaNovartisN/ARare genetic
AAV9-LAMP2Rocket PharmaceuticalsNov 19, 2018Rare genetic
You're viewing 2 of 12 licensing deals. Get the full list »